secwatch.observer — SEC 8-K summary
======================================

Issuer:     USANA HEALTH SCIENCES INC (USNA)
CIK:        0000896264
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001157523-23-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

USANA reports preliminary FY2022 net sales ~$995M, EPS ~$3.65; guides FY2023 net sales $850-950M, EPS $2.35-$3.30
--------------------------------------------------------------------------------

- Preliminary FY2022 net sales ~$995M, diluted EPS ~$3.65, above prior guidance of $955-975M and $3.15-$3.40.
- Active Customers ~490,000 at year-end; incremental sales in China from COVID policy shift, but uncertainty persists.
- Initial FY2023 guidance: net sales $850-950M, diluted EPS $2.35-$3.30, reflecting lower starting customer base and currency headwinds.
- Company to report final Q4/FY2022 results on Feb 7, 2023; conference call Feb 8.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/0001157523-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/a53173940.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer